CL2023000037A1 - Therapeutic RNA for HPV-positive cancer - Google Patents

Therapeutic RNA for HPV-positive cancer

Info

Publication number
CL2023000037A1
CL2023000037A1 CL2023000037A CL2023000037A CL2023000037A1 CL 2023000037 A1 CL2023000037 A1 CL 2023000037A1 CL 2023000037 A CL2023000037 A CL 2023000037A CL 2023000037 A CL2023000037 A CL 2023000037A CL 2023000037 A1 CL2023000037 A1 CL 2023000037A1
Authority
CL
Chile
Prior art keywords
hpv
cancer
positive cancer
positive
therapeutic rna
Prior art date
Application number
CL2023000037A
Other languages
Spanish (es)
Inventor
Sahin Ugur
Kreiter Sebastian
Diken Mustafa
Vascotto Fulvia
Salomon Nadja
Grunwitz Christian
Original Assignee
BioNTech SE
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical BioNTech SE
Publication of CL2023000037A1 publication Critical patent/CL2023000037A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se relaciona con el campo del ARN terapéutico para tratar el cáncer positivo para VPH, en particular, los cánceres anogenitales, cervicales y de pene y el cáncer en la región de la cabeza y el cuello, tal como el cáncer en la región genital y el carcinoma de células escamosas de cabeza y cuello (HNSCC). En el presente documento se describen composiciones, usos y métodos para el tratamiento de cánceres positivos para VPH. La administración de ARN terapéuticos a un paciente que tiene cáncer VPH positivo descrito en este documento puede reducir el tamaño del tumor, prolongar el tiempo hasta la progresión de la enfermedad y/o proteger contra la metástasis y/o la recurrencia del tumor y, en última instancia, prolongar el tiempo de supervivencia.This invention relates to the field of therapeutic RNA for treating HPV positive cancer, in particular, anogenital, cervical and penile cancers and cancer in the head and neck region, such as cancer in the genital region. and head and neck squamous cell carcinoma (HNSCC). Described herein are compositions, uses and methods for the treatment of HPV-positive cancers. Administration of therapeutic RNAs to a patient who has HPV-positive cancer described herein may reduce tumor size, prolong time to disease progression, and/or protect against tumor metastasis and/or recurrence and, in ultimately prolong survival time.

CL2023000037A 2020-07-07 2023-01-05 Therapeutic RNA for HPV-positive cancer CL2023000037A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20069146 2020-07-07

Publications (1)

Publication Number Publication Date
CL2023000037A1 true CL2023000037A1 (en) 2023-10-13

Family

ID=88840011

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000037A CL2023000037A1 (en) 2020-07-07 2023-01-05 Therapeutic RNA for HPV-positive cancer

Country Status (1)

Country Link
CL (1) CL2023000037A1 (en)

Similar Documents

Publication Publication Date Title
MX2019001920A (en) Rna for cancer therapy.
CL2020000501A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and their uses.
MX2020009773A (en) Combination therapy.
EA201790404A1 (en) MACROPINOCYTOZING HUMAN ANTI-CD46 ANTIBODIES AND TARGET TREATMENT OF CANCER
MX2019010202A (en) Glycan-interacting compounds and methods of use.
MY189713A (en) Duocarmycin adcs for use in treatment of endometrial cancer
MX2019003134A (en) Combination therapy.
MX2020001727A (en) Combination therapy.
AR110730A1 (en) LISTERY AND METHOD RECOMBINANT VACCINE VACCINES FOR USE IN CANCER IMMUNOTHERAPY
MX2019013862A (en) Combination therapy.
ECSP21006416A (en) FORMULATIONS OF AN AXL / MER INHIBITOR
CL2020000508A1 (en) Anti-egfr drug-antibody (adc) conjugates and their uses.
CL2020000270A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor.
MX2020013601A (en) Cancer-specific t-cell receptors.
MX2018010223A (en) Combination therapy for treatment of ovarian cancer.
CL2023000037A1 (en) Therapeutic RNA for HPV-positive cancer
CO2023001133A2 (en) therapeutic rna for hpv positive cancer
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
AR095416A1 (en) TREATMENT WITH CUTIRSEN THAT PRESENTS A REDUCED TOXICITY
AR122341A1 (en) METHOD FOR THE TREATMENT OF CANCER USING ARTIFICIAL ADJUVANT CELL (AAVC)
AR111803A1 (en) DERIVED FROM CICLOPENTAN [G] QUINAZOLIN-4-ONA AND ITS EMPLOYMENT IN THE TREATMENT OF CANCER RESISTANT TO PLATINUM
MX2022014231A (en) ANTIBODY-DRUG CONJUGATES TARGETING uPARAP.
CL2018002438A1 (en) Method and composition for the treatment of cancer or a skin lesion using a vaccine.
CL2021001623A1 (en) Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in treating cancer
MX2021001764A (en) Combination therapy.